Moderna Inc.’s stock erased early losses to gain more than 3% on Friday, after the biotech company posted a wider-than-expected fourth-quarter loss and offered soft guidance for 2025, offsetting ...

HHS cites need for review due to 'oversight' issues CDC states low risk of H5 bird flu to public Moderna's shares drop 5.5% Feb 26 (Reuters) - U.S. health officials are reevaluating a $590 million ...

Trump Administration Weighs Pulling Funding for Moderna Bird Flu Vaccine, Bloomberg News Reports (Reuters) - U.S. health officials are reevaluating a $590 million contract that was awarded to ...

Investors with a lot of money to spend have taken a bullish stance on Moderna MRNA. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

US health officials are reevaluating a $590 million contract for bird flu shots that the Biden administration awarded to Moderna Inc., people familiar with the matter said. The review is part of a ...

Meanwhile, despite a downgrade from Barclays, Moderna jumped over 8% on Tuesday, mainly due to management’s comment on prioritizing 10 high-value programs with possible approval over the next ...

Friday marked the worst day of the year for the stock market as the Dow lost 748.63 points, however, pharmaceutical companies stood out as a glaring exception, with both Pfizer and Moderna stocks ...

Shares of Moderna (MRNA), Pfizer (PFE) and Novavax (NVAX) all gained Friday, a broadly downbeat session that saw the S&P 500 slide 1.7%. Moderna was the biggest gainer on the benchmark index ...

Investing.com -- Shares of Moderna (NASDAQ: NASDAQ:MRNA) climbed 5%, while Biontech and Pfizer (NYSE:PFE) saw increases of 3% and 1% respectively, following reports of a new coronavirus with ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against firms that kick off shortened trading week with impressive gains. The stock market kicked off the ...

One notable vaccine maker, however, is struggling. Moderna reported Q4 and 2024 earnings last week, revealing full-year revenue of just over $3 billion—less than half of the nearly $7 billion the ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the 3% gain from Friday when it reported fourth-quarter 2024 financial results.